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domised controlled trials, our systematic review lends
support to the hypothesis that NSAIDs may protect
against the development of Alzheimer’s disease. The
appropriate dose, duration, and ratios of risk to benefit
are still unclear.
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Prevalence of five common clinical abnormalities in very
elderly people: population based cross sectional study
A J M de Craen, J Gussekloo, Y K O Teng, P W Macfarlane, R G J Westendorp
As the prevalence of disease rises with age, the number
of people with unidentified abnormalities is also likely
to increase. We assessed the number of previously
known and newly identified patients with anaemia,
diabetes mellitus, thyroid dysfunction, atrial fibrillation,
and hypertension in a population based sample of 85
year old people.
Participants, methods, and results
The study design and baseline characteristics of the
599 participants in the Leiden 85 plus study have been
published elsewhere.1 All participants gave informed
consent. We used standard laboratory techniques to
identify anaemia, diabetes mellitus, and thyroid
dysfunction. Atrial fibrillation, including flutter, was
identified on an electrocardiogram. Hypertension was
identified by averaging two standardised blood
pressure readings measured with a sphygmomanom-
eter at two separate visits. For 40 people a blood sam-
ple, electrocardiogram, or blood pressure measure-
ment was not available. Furthermore, we excluded all
31 residents of nursing homes because they do not
voluntarily consult a general practitioner but are
continuously monitored by a nursing home physician.
We obtained the medical history of the 528
remaining people from their general practitioner. By
including a local general practitioner (JG) in our
research team, we managed to get all 60 general prac-
titioners in Leiden to cooperate with us. Moreover, all
pharmacies in Leiden provided detailed information
on prescribed drugs for all patients. All drugs were
encoded according to the WHO Anatomical Thera-
peutic Chemical (ATC) classification.2
Abnormalities were considered known when a
positive medical history was present or when patients
were currently using one of the following ATC coded
drugs: B03 for anaemia, A10 for diabetes mellitus, H03
for thyroid dysfunction, B01AA04/B01AA07 com-
bined with C01AA05 for atrial fibrillation, or C02, C03,
C07, C08, or C09 for hypertension.
The definitions for newly identified clinical abnor-
malities were: haemoglobin < 130 g/l ( < 8.1 mmol/l)
in men or < 120 g/l ( < 7.5 mmol/l) in women for
anaemia3; non-fasting serum glucose concentrations
> 11.0 mmol/l for diabetes mellitus; serum thyroid
stimulating hormone < 0.3 mU/l and serum free thy-
roxin > 24 pmol/l (hyperthyroidism) or thyroid stimu-
lating hormone > 4.8 mU/l and free thyroxin < 10
pmol/l (hypothyroidism) for thyroid dysfunction; Min-
Papers
Section of
Gerontology and
Geriatrics,
Department of
General Internal
Medicine, Leiden
University Medical
Centre, PO Box
9600, 2300 RC,
Leiden, Netherlands
A J M de Craen
senior epidemiologist
J Gussekloo
general practitioner
Y K O Teng
medical student
R G J Westendorp
professor
University of
Glasgow,
Department of
Medical Cardiology,
Royal Infirmary,
Glasgow, G31 2ER
P W Macfarlane
professor
Correspondence to:
A J M de Craen
craen@lumc.nl
BMJ 2003;327:131–2
131BMJ VOLUME 327 19 JULY 2003 bmj.com
nesota codes 8-3-1 or 8-3-24 for atrial fibrillation or
flutter; and systolic pressure > 160 mm Hg or diastolic
pressure > 95 mm Hg for hypertension.5
Among the 528 participants 38 were known to
have anaemia, 77 had diabetes mellitus, 32 had thyroid
dysfunction, 32 had atrial fibrillation, and 304 had
hypertension (table). We newly identified 118 with
anaemia, 9 with diabetes mellitus, 6 with thyroid
dysfunction, 23 with atrial fibrillation, and 73 with
hypertension (table). Over 90% of all participants,
except for those with newly identified atrial fibrillation,
had consulted their general practitioner at least once in
the year before the study.
Comment
Using information from general practitioners and
pharmacy records combined with five simple and
readily available procedures we have obtained reliable
estimates of the prevalence of five common clinical
abnormalities in very elderly people. We found a con-
siderable number with previously undetected anaemia
and hypertension but fewer with previously undetected
thyroid dysfunction, atrial fibrillation, and diabetes
mellitus. We have shown that our criteria for anaemia,
diabetes mellitus, thyroid dysfunction, and hyper-
tension are adequate for elderly people and can serve
as guidelines for clinicians treating older patients.
Experienced staff reviewed all automated interpreta-
tions and codings of electrocardiograms for atrial
fibrillation so we consider that our interpretation of
this abnormality is completely reliable. In conclusion,
we have shown that it is feasible to use these investiga-
tive procedures in an elderly population to provide
important quantitative information for future discus-
sions on screening elderly people.
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Longevity and carrying the C282Y mutation for
haemochromatosis on the HFE gene: case control study of
492 French centenarians
Hélène Coppin, M Bensaid, S Fruchon, N Borot, H Blanché, M P Roth
Hereditary haemochromatosis is a common auto-
somal recessive disorder of iron metabolism. Most
patients are homozygous for a C282Y mutation in the
HFE gene. This mutation is frequent in northern
Europe, where one in five to ten people are carriers.
People who are heterozygous for the C282Y mutation
have slightly but significantly higher values for serum
iron and transferrin saturation and are less likely to
have anaemia because of iron deficiency.1 2
Iron promotes the generation of free radicals, which
leads to mutagenesis, atherosclerosis, inflammation, and
bacterial growth. Therefore, genotypes that increase the
concentrations of iron for transport and storage may be
associated with an increased risk for common diseases,
such as cancers and cardiovascular diseases, and for
inflammatory and infectious conditions. Other studies,
which investigated the associations of C282Y heterozy-
gosity with morbidity, found conflicting results, and con-
sensus has not been reached about whether C282Y is
associated with the development of extrahepatic
cancers, coronary heart disease, or diabetes.1 2
We hypothesised that people who are heterozygous
for the C282Y mutation are under-represented in a
centenarian population because many would have died
younger from life threatening diseases which are more
prevalent in C282Y heterozygotes.
Participants, methods, and results
We recruited 492 French centenarians, who consented
personally, through the Chronos Project at the
Foundation Jean Dausset (Centre d’Etude du Polymor-
Number (percentage) of people previously known and newly identified with clinical abnormalities in population of 528 people aged 85
years and their contact with general practitioner in year before study
Clinical abnormality
Abnormality No GP contact
Known Newly identified Known Newly identified
Anaemia 38 (24) 118* (76) 0/38 (0) 8/118 (7)
Diabetes mellitus 77 (90) 9 (10) 4/77 (5) 0/9 (0)
Thyroid dysfunction 32 (84) 6 (16) 3/32 (9) 0/6 (0)
Atrial fibrillation 32 (58) 23 (42) 0/32 (0) 5/23 (22)
Hypertension 304 (81) 73 (19) 15/304 (5) 7/73 (10)
*Mean corpuscular volume <80 fl in six participants and >100 fl in six participants.
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